A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Study Overview
=================
Brief Summary
-----------------
A non-randomized, open, Simon'soptimal2-stage study to evaluate the efficacy and safety of 6MW3211 in patients with advanced Lung Cancer who had failed therapy with PD-1/L1 Inhibitor.

Detailed Description
-----------------
36 to 64 patients with advanced lung cancer who failed pD-1 /L1 inhibitor treatment will be inrolled. Cohort 1:20 to 33 patients with non-small cell lung cancer (NSCLC) Cohort 2:16 to 31 patients with small cell lung cancer (SCLC)

Official Title
-----------------
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer Who Had Failed Therapy With PD-1/L1 Inhibitor

Conditions
-----------------
Advanced Lung Cancer

Intervention / Treatment
-----------------
* Drug: 6MW3211


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: years≥18 cohort1：Locally advanced or metastatic NSCLC (stage IIIB-IV) confirmed by histological or cytological evidence that cannot be treated with radical surgical resection and cannot be treated with radical synchronous/sequential chemoradiotherapy. cohort2:Extensive stage small cell lung cancer (ES-SCLC) confirmed byhistologically or cytologically 3.Patients who had failed therapy with PD-1/L1 Inhibitor. 4.≥5 slides of unstained tumor tissue should be provided 5.EGFR, ALK, ROS1 were negative 6.ECOG 0 or 1 7.At least one extracranial measurable target evaluated by RECIST1.1 8.Expected survival≥3 months 9.Suitable organs and hematopoietic functions 10.Women and men of reproductive age must agree to use effective contraception from the date of signing the informed consent until 6 months after the last administration of 6MW3211 injection, and women of reproductive age must have negative serum pregnancy test results within 7 days prior to administration. 11.Sign informed consent voluntarily - Exclusion Criteria: Patients who had received immunotherapy other than pD-1 /L1 inhibitors Patients who were discontinued due to grade ≥3 serious immune-related adverse events (irAE) when treated with a PD-1/L1 inhibitor Patients who had received anti-PD-1 /L1 inhibitor,have had immune pneumonia or immune myocarditis Patients who had malignant tumors other than NSCLC or SCLC within 5 years Patients with active central nervous system (CNS) metastasis or meningeal metastasis. Adverse reactions related to previous treatments failed to recover to CTCAE 5.0 ≤1 patients with autoimmune diseases that are likely to recur Patients with history of interstitial lung disease or have non-infectious pneumonia Uncontrolled systemic diseases after treatment. Patients with active tuberculosis Patients with severe infection or requiring antibiotic treatment within the first 4 weeks prior to initial administration Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage Prior blood transfusion or hematopoietic stimulator therapy within 4 weeks prior to initial dosing Patients who have previously received antitumor therapy Patients requiring systemic glucocorticoids or other immunosuppressive agents within 14 days prior to initial dosing or during the study period Patients who were allergic to any composition of investigational drug Patients with chronic active hepatitis B or active hepatitis C Patients who received other investigational drugs within 4 weeks prior to initial dosing Patients who underwent major surgery within 30 days prior to first administration History of drug or substance abuse in the past 1 year Live vaccine was administered within 30 days prior to first administration Have the history of neuropsychiatric disorders Women who are pregnant or breastfeeding Patients had other factors that might have forced them to terminate the study by investigator's judgment -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 6MW3211<br>6MW3211injection,30mg/kg,Q2W | Drug: 6MW3211<br>* 6MW3211 injection ,30mg/kg,iv drip，Q2W<br>* Other names: 6MW3211injection;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ORR | The percentage of (PR+CR) after treatment to the total number of cases was calculated | up to 24mouths or intolerable toxicity, disease progression or death, patient withdrawal of informed consent, withdrawal from the study and so on |